Physician profile
David Alderman
NPI 1467419523
$2,648.46
in general payments reported to CMS, 2019-2025
13 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $173 · 2021: $168 · 2022: $208 · 2023: $870 · 2024: $651 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $695.46 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals LP | $609.05 | 2023-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $494.12 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Aurinia Pharma U.S., INC. | $165.71 | 2021-2022 | |
| Travere Therapeutics, INC. | $137.46 | 2022-2025 | |
| Baxter Healthcare | $134.55 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $131.23 | 2023 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $124.85 | 2022 | |
| Vifor Pharma, INC. | $55.76 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.11 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $29.50 | 2024 | |
| Calliditas Therapeutics US INC. | $21.18 | 2022 | |
| Fresenius USA Marketing, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.